← Eichor
Study identifier: NCT05761054 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Sarcoma Preoperative Radiation With Simultaneous INTegrated Boost (SPRINT)

Condition: Soft Tissue Sarcoma  ·  Sponsor: Azienda Ospedaliero-Universitaria Careggi

PhaseNA
Planned participants33
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Intervention prospective monocentric one arm study on the use of neoadjuvant radiotherapy with simultaneous integrated boost (Simultaneous Integrated Boost, SIB) in patients with STS with indication for preoperative radiotherapy. The treatment will be administered in 25 daily fractions (Monday-Friday) at the disease site to include the region of suspected micrometastatic spread (Clinical Target Volume 1, CTV1) at a dose of 50 Gy (2Gy / fraction) with SIB intensification on volume reduced corresponding to the interface sites between the tumor and the vascular / nerve axes (Clinical Target Volume 2, CTV2) at a dose of 60 Gy (2.4 Gy / fraction). The association with neoadjuvant chemotherapy based on anthracyclines is allowed.

This description comes directly from the study's public registry record.

Talk to the study team

Marta Pacinico  ·  0557947192  ·  marta.pacinico@unifi.it

Always discuss trial participation with your own doctor first.

Locations (1)

AOU CareggiFlorence, Fi, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05761054